New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
16:15 EDTHPQ, GME, PTCT, ARO, ARUNOn The Fly: Closing Wrap
Stocks on Wall Street opened in quiet fashion, though with an upward bias, and proceeded to trade that way throughout the session. The averages drifted higher in a broad based move that saw each of the major averages tack on gains of at least 0.3%. The volume was light, as was to be expected prior to a holiday weekend, and there was little volatility as the market moved in a narrow range once it found its level. Ending the week on a high note, the benchmark S&P 500 managed to close above 1,900 for the first time. ECONOMIC EVENTS: In the U.S., new home sales rose 6.4% in April to a rate of 433K. The percentage increase trailed expectations, but the rate was higher than expected due to upward revisions to last months figures. COMPANY NEWS: Shares of Hewlett-Packard (HPQ) rose $2.00, or 6.1%, to $33.72 after the computer and printer making giant reported second quarter adjusted earnings per share that matched estimates and announced additional job cuts. Following the report, Citigroup said it sees "meaningful upside" to the stock and believes HP's cost savings are underappreciated. After HP's report of roughly in-line results and more layoffs, Wells Fargo noted that HP said it was more confident in its growth outlook. The firm thinks the layoffs may reflect newly discovered cost cutting opportunities, rather than end market pressures, and kept an Outperform rating on the shares. MAJOR MOVERS: Among the notable gainers was PTC Therapeutics (PTCT), which surged $4.71, or 30.74%, to $20.03 after the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion regarding the company's application for a conditional marketing authorization of Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy. Also higher was video game retailer GameStop (GME), which rose $1.55, or 4.2%, to $38.43 after the company reported better than expected first quarter profits and backed its fiscal 2014 guidance. Among the noteworthy losers following their earnings reports were apparel retailer Aeropostale (ARO), which fell $1.09, or 24.12%, to $3.43, and network solutions provider Aruba Networks (ARUN), which slid $2.17, or 10.82%, to $17.89. INDEXES: The Dow was up 63.19, or 0.38%, to 16,606.27, the Nasdaq was up 31.47, or 0.76%, to 4,185.81, and the S&P 500 was up 8.04, or 0.42%, to 1,900.53.
News For HPQ;GME;PTCT;ARO;ARUN From The Last 14 Days
Check below for free stories on HPQ;GME;PTCT;ARO;ARUN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 14, 2014
15:24 EDTHPQHewlett-Packard volatility increases into Q3 and outlook
Subscribe for More Information
10:05 EDTARUNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:11 EDTARUNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Kohl's (KSS), up 2.5%... Plug Power (PLUG), up 10%... Perrigo (PRGO), up 4.5%. HIGHER: Aruba Networks (ARUN), up 3% after shares upgraded at Stifel... KaloBios (KBIO), up 7.9% after publication shows EphA3 as target for anticancer therapy... Supernus (SUPN), up 4.4% after receiving FDA fast track designation for SPN-810. DOWN AFTER EARNINGS: Noodles & Company (NDLS), down 22%... Vipshop (VIPS), down 5.8%. LOWER: ExOne (XONE), down 10.7%, Voxeljet (VJET), down 6.6%, after earnings reports. Peers in the 3D space are lower as well, with Stratasys (SSYS) down 1% and 3D Systems (DDD) down 0.2%... Enphase Energy (ENPH), down 2.6% after filing to sell common stock for holders... InterMune (ITMN), down 3% after downgraded at Goldman following yesterday's advance on Bloomberg report that the company received takeover bids from Sanofi (SNY), Roche (RHHBY).
07:50 EDTARUNAruba Networks upgraded at Stifel
As previously reported, Stifel upgraded Aruba to Buy from Hold. The firm upgraded shares following checks that indicate solid momentum and reduced pricing pressures. Price target is $24.
06:17 EDTARUNAruba Networks upgraded to Buy from Hold at Stifel
Subscribe for More Information
06:09 EDTHPQGoogle, HP in talks to collaborate on 'virtual assistant,' The Information says
Subscribe for More Information
August 13, 2014
07:55 EDTHPQHP free cash flow upside thesis intact, says Brean Capital
Subscribe for More Information
07:45 EDTARUNAruba Networks checks show sales ahead of plan, says JMP Securities
Subscribe for More Information
August 12, 2014
12:31 EDTAROAbercrombie upgraded at Stifel citing better assortment, trimmed costs
Shares of Abercrombie & Fitch (ANF) were upgraded by research firm Stifel this morning, though the retailer's shares are slightly lower in early afternoon trading. WHAT'S NEW: Stifel analyst Richard Jaffe upgraded Abercrombie & Fitch to Buy from Hold, citing the retailer's better merchandise assortment and reshaped cost structure. Jaffe feels that Abercrombie & Fitch had been running with overblown expenses and believes that having a slimmer cost structure will allow the company to influence sales better and boost future EPS. The analyst raised his Q4 EPS estimate to $1.94 from $1.87, his FY14 EPS estimate to $2.50 from $2.43 and his FY15 EPS estimate to $3.40 from $3.14. Over the next year, Jaffe said that he expects A&F shares will be valued for the company's effort to win back customers at its Hollister and Abercrombie stores. Still, he said that Q3 could continue to be a struggle for the retailer due to external obstacles that are still a headwind. The firm maintains a $50 price target on the retailer's shares. WHAT'S NOTABLE: Analysts at Wunderlich also initiated coverage of the stock this morning with a Buy rating and a $48 price target. PRICE ACTION: During early afternoon trading, shares of Abercrombie & Fitch fell 9c, or 0.2%, to $41.47. OTHERS TO WATCH: Rivals to Abercrombie & Fitch include Aeropostale (ARO), Urban Outfitters (URBN), and American Eagle Outfitters (AEO).
11:10 EDTAROHigh option volume stocks
High option volume stocks: ACM KATE ARO TKMR ODP ICPT GPI FENG LINTA NDLS
10:31 EDTHPQEx-Autonomy CFO accuses HP of agreement cover-up, Re/code says
Subscribe for More Information
10:00 EDTAROOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:57 EDTPTCTPTC Therapeutics management to meet with Oppenheimer
Meeting to be held in Toronto on August 18 hosted by Oppenheimer.
08:42 EDTAROAeropostale initiated with a Hold at Wunderlich
Subscribe for More Information
August 11, 2014
15:27 EDTPTCTWedbush to hold a conference
Life Sciences Management Conference to be held in New York on August 12-13.
15:24 EDTHPQBloomberg to hold a summit
Silicon Valley 2014 Cybersecurity Summit to be held in Palo Alto, California on August 12.
August 7, 2014
14:05 EDTPTCTPTC Therapeutics reports publication of preclinical study results in SMA models
PTC Therapeutics (PTCT) announced that he journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficits in mouse models of Spinal Muscular Atrophy or SMA. Stuart Peltz, CEO of PTC Therapeutics, said, "Using the experience and expertise in RNA biology we have gained at PTC over the last 16 years, we used our alternative splicing technology to identify and subsequently optimize investigational compounds that target the SMN2 splicing to produce the SMN protein. Our unique partnership with Roche and the SMA Foundation has allowed this project to rapidly move into clinical development." Luca Santarelli, Head of Neuroscience, Ophthalmology and Rare Diseases at Roche (RHHBY), said, "Although still preclinical, these results demonstrate how SMN2 splicing modifiers could correct the molecular deficit that causes SMA. This study represents an important step towards developing a potential therapeutic option for this devastating and currently untreatable condition. Early clinical trials are currently underway to determine the safety and tolerability of this approach."
07:41 EDTPTCTPTC Therapeutics reports Q2 EPS (86c), consensus (75c)
Reports Q2 revenue $1.68M, consensus $1.71M.
06:48 EDTPTCTPTC Therapeutics files automatic mixed securities shelf
August 6, 2014
10:37 EDTHPQHewlett-Packard volatility increases into Q3
Hewlett-Packard August call option implied volatility is at 23, August is at 39, September is at 29, January is at 26; compared to its 26-week average of 30 according to Track Data, suggesting large price movement into the expected release of Q3 results on August 20.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use